- Home
- TBPH
as 11-20-2024 4:00pm EST
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | GEORGE TOWN, GRAND CAYMAN |
| Market Cap: | 418.7M | IPO Year: | N/A |
| Target Price: | $13.75 | AVG Volume (30 days): | 191.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.44 - $11.71 | Next Earning Date: | 11-12-2024 |
| Revenue: | $63,192,000 | Revenue Growth: | 15.93% |
| Revenue Growth (this year): | 6.93% | Revenue Growth (next year): | 45.31% |
Stock Insider Trading Activity of Theravance Biopharma Inc. (TBPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farnum Rhonda | TBPH | SVP, COMM & MEDICAL AFFAIRS | Nov 11 '24 | Sell | $9.00 | 4,000 | $36,000.00 | 322,743 |
Latest Theravance Biopharma Inc. News
TBPH Breaking Stock News: Dive into TBPH Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Theravance Biopharma to Participate in an Upcoming Investor Conference
Simply Wall St.
7 days ago
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
8 days ago
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
GuruFocus.com
8 days ago
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
Zacks
9 days ago
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
PR Newswire
9 days ago
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
Zacks
10 days ago
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Zacks
10 days ago
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Compare TBPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TBPH Theravance Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.